Successful financing round for 4GENE
The biotech company 4GENE has closed its investment round with a high six-figure sum. In addition to the founding shareholders, Goldmann International and MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg participated in the financing round.
“We are very pleased that we can now identify further drug candidates for the pharmaceutical industry as well as push the further expansion of our technology platform”, says Heimo Adamski, CEO of 4GENE. The biotech startup develops and produces fragrances. The so-called fragrance glucosides have, among other things, the advantage that they can be activated at a specific time. The technology has already been successfully implemented for paracetamol, which was converted into a glycoside in trials. 4GENE has already filed a patent application for the paracetamol derivative, which is expected to enable a more predictable and gentle uptake by the human organism.
Unique technology platform
Originally, the technology was developed for fragrances and flavorings in the cosmetics and perfume industry to ensure a fragrance experience in creams, lotions and perfumes over a certain period of time by slowly releasing the substances. The mechanism can also be used in the food industry and for medicines. In the case of an active ingredient, release in the body occurs through microbial or human glucosidases, optionally via saliva upon ingestion as well as later in the intestine.
“4GENE’s technology platform is unique. The company has managed to make this glycosylation suitable for mass production and reinvent applications in a wide range of industries. Therefore, the decision to increase our investment was easy for us”, says Mattias Götz, head of the VC fund at MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg.
Cooperation partners sought
The platform technology can be used for a wide range of small molecules of various types — flavors, fragrances and active pharmaceutical ingredients. The respective products can be easily further processed by industry, even with existing processes.
“With this technology, we are enabling a new possibility for patenting already existing substances. We are already working with some companies at the trial level, and we welcome other partners from industry — whether cosmetics, food, mechanical engineering or pharmaceuticals — to develop market-ready products,” explains Heimo Adamski.
The platform technology is continuously optimized, the library of active and other glycosylated substances is constantly expanding and is available to industry at short notice.